NovoCure Ltd Announces Japan MHLW Approval for Optune Pax in Pancreatic Cancer

What Happened

• NovoCure Ltd announced on September 15, 2026 (disclosed in an 8-K filed October 1, 2026) that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Optune Pax® for the treatment of adult patients diagnosed with unresectable locally advanced pancreatic cancer, to be used concomitantly with gemcitabine and nab‑paclitaxel. The company made the disclosure under Regulation FD (Item 7.01).

Key Details

• Approvaling authority: Japan MHLW; indication: unresectable locally advanced pancreatic cancer in adults.
• Approved combination therapy: Optune Pax with gemcitabine and nab‑paclitaxel.
• Disclosure timeline: press release dated September 15, 2026; Form 8-K filed October 1, 2026 (Exhibit 99.1 is the press release).
• Legal note in filing: the information is a Regulation FD disclosure and is not “filed” for purposes of Section 18 of the Exchange Act.

Why It Matters

• Regulatory approval permits NovoCure to market Optune Pax for this pancreatic cancer indication in Japan, potentially expanding its addressable market in a major oncology market.
• The filing contains no financial guidance, revenue projections, or commercial terms — investors should note this is a product approval announcement, not a financial update.
• This is a material regulatory development for NovoCure’s oncology portfolio and may affect future commercialization and adoption in Japan; watch for subsequent updates on launch timing, pricing, reimbursement, and sales guidance.